| Autor: |
Tennen RI; 23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA, 94086, USA., Laskey SB; 23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA, 94086, USA., Koelsch BL; 23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA, 94086, USA., McIntyre MH; 23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA, 94086, USA., Tung JY; 23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA, 94086, USA. joyce@23andme.com. |
| Abstrakt: |
Current guidelines recommend BRCA1 and BRCA2 genetic testing for individuals with a personal or family history of certain cancers. Three BRCA1/2 founder variants - 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) - are common in the Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish founder variants, evaluating two characteristics that are typically used to recommend individuals for BRCA testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information, 21% did not self-report Jewish ancestry; of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided both ancestry and family history information, 44% did not have a first-degree family history of a BRCA-related cancer and, in the absence of a personal history of cancer, would therefore be unlikely to qualify for clinical genetic testing. These findings may help inform the discussion around broader access to BRCA genetic testing. |
